NitroMed's BiDil Pricing: Test for a Whole Class of New Companies

After putting two generics together and then getting the product approved for a new indication, NitroMed priced its new drug above expectations. But will the old-style pricing strategy hold up in a managed care world?

Ellen Licking

These have been heady days for NitroMed Inc. On June 23, the Food and Drug Administration approved the company's...

More from Business Strategy

More from In Vivo